Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?
This article was originally published in Pharmaceutical Approvals Monthly
Upsher-Smith’s recent acquisition of research boutique Proximagen highlights the dynamics of the market: specialty pharma extending dominance and introducing new agents to the market, while most early R&D activity originates at small firms. But it may be difficult for this combination of players to bring forth the game-changing therapies that are needed, given the technical challenges of the disease space.
You may also be interested in...
Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.